Glioblastoma is an uncommon primary brain tumor accounts for upto 15.4% of all primary brain tumors.
Although several modern therapies against glioma are discovered, management is still a critical
concern. The existing therapies were relatively inconsistent; moreover, the procedures as well are difcult to treat. These
ineffective therapeutic approaches led researchers to identify the novel biomarkers that can be implemented with the existing
therapies for better management. In this view, along with biomarker research, a literature search for exosomal PTEN detection in
glioblastoma was conducted and the recent studies observed that exosomes can transport tumor-suppressive proteins (PTEN)
and oncogenic mRNAs, microRNAs to a recipient cell, which subsequently activates the downstream signaling pathways and
inuences the cellular phenotype. These exosomes facilitate the transfer of PTEN released from tumor cells to receipt cells that
leads to tumor progression. Similarly, glioma was also associated with a reduction or loss of PTEN expression. Hence, our
present review aimed to provide a holistic picture of glioblastoma, its pathogenesis and novel biomarkers with an emphasis on
PTEN detection in exosomes for the early identication of glioblastoma